The IL-17A-induced expression of downstream inflammatory effectors IL-6, CXCL1 and MMP3 was completely inhibited by secukinumab, suggesting that IL-17A alone and in concert with TNF-α may promote inflammation in tendinopathy. Here, CXCL1 is linked to disease of the tendon.